# Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

Study · id `cardio:ct-nct02833948` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02833948](<https://clinicaltrials.gov/study/NCT02833948>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02833948

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 231 participants.

## Technical summary

Registry record NCT02833948. Randomized; single masking; primary purpose diagnostic. Start 2016-05 (registry gives no type); primary completion 2018-12 (actual). Results posted on 2020-01-18.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 231 participants (enrolled count; ClinicalTrials.gov record NCT02833948, source copy `cardio:ctgov-nct02833948-2020-01-18`, retrieved 2026-10-26)
- Start date: 2016-05 (registry gives no type) (ClinicalTrials.gov record NCT02833948, source copy `cardio:ctgov-nct02833948-2020-01-18`, retrieved 2026-10-26)
- Primary completion: 2018-12 (actual) (ClinicalTrials.gov record NCT02833948, source copy `cardio:ctgov-nct02833948-2020-01-18`, retrieved 2026-10-26)
- Completion: 2019-03-06 (actual) (ClinicalTrials.gov record NCT02833948, source copy `cardio:ctgov-nct02833948-2020-01-18`, retrieved 2026-10-26)
- Results first posted: 2020-01-18 (ClinicalTrials.gov record NCT02833948, source copy `cardio:ctgov-nct02833948-2020-01-18`, retrieved 2026-10-26)
- Countries: United States; Canada; Denmark; Germany; Netherlands; Sweden; Switzerland (ClinicalTrials.gov record NCT02833948, source copy `cardio:ctgov-nct02833948-2020-01-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02833948-2020-01-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
- Acronym: GALILEO-4D
- Condition: Aortic Valve Stenosis
- Condition: Cardiovascular Diseases
- Condition: Heart Valve Diseases
- Condition: Ventricular Outflow Obstruction
- Condition: Thrombosis
- Intervention (Drug): Acetylsalicylic acid
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Rivaroxaban
- Lead sponsor: ECRI bv
- Lead sponsor class: INDUSTRY
- Collaborator: Copenhagen University Hospital, Rigshospitalet
- Collaborator class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY
- Collaborator: Cardialysis BV
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: ECRI bv (`cardio:org-ecri-bv`)
- Registry lists this organization as a collaborator: Copenhagen University Hospital, Rigshospitalet (`cardio:org-copenhagen-university-hospital-rigshospitalet`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)
- Registry lists this organization as a collaborator: Cardialysis BV (`cardio:org-cardialysis-bv`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement (`cardio:pubmed-31733182`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1d660771d11f354c419bc1395c194269b393f2de41d4119265df73574f209653
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
